Cargando…

Acquired Brain Injury-Induced Hyperphagia and Obesity, Successfully Treated With a GLP-1 Agonist

Background: Several Glucagon-like peptides 1 (GLP-1s) were approved since 2005 for the treatment of DM & obesity. Their usefulness in other conditions is not well studied. We present two cases of hyperphagia after TBI successfully treated with GLP-1 agonists. Clinical cases: Case 1: A 54-year-ol...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ngu, Michael, Blocher, Nissa, Segal, Miriam
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Adipose Tissue, Appetite, and Obesity
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8265742/ http://dx.doi.org/10.1210/jendso/bvab048.063

Ejemplares similares

FRI064 The Role Of GLP-1 Receptor Agonists In The Treatment Of Pituitary And Hypothalamic Tumor Induced Obesity
por: Botero Suarez, Carlos S, et al.
Publicado: (2023)

SUN-609 Livoletide (AZP-531), an Unacylated Ghrelin Analogue, Improves Hyperphagia and Food-Related Behaviors Both in Obese and Non-Obese People with Prader-Willi Syndrome
por: Harisseh, Rania, et al.
Publicado: (2020)

Mice Deficient for an Intestinal G Protein-Coupled Receptor Expression Have Increased Satiety During Rebound Hyperphagia
por: Yan, Shijun, et al.
Publicado: (2021)

SUN-608 Juvenile Toxicity Study of Livoletide: A Peptide Analogue of Unacylated Ghrelin for the Treatment of Hyperphagia in Prader-Willi Syndrome
por: Xu, Howard, et al.
Publicado: (2020)

FRI067 Efficacy And Safety Of Glucagon-like Peptide 1 Analogs And Agonists (aGLP1) In Overweight/Obese Patients: A Systematic Review And An Updated Network Meta-analysis
por: Silva, Caroliny Hellen, et al.
Publicado: (2023)

MON-102 Nonclinical Development of AZP-531 (Livoletide): A Peptide Analog of Unacylated Ghrelin for the Treatment of Hyperphagia in Prader-Willi Syndrome
por: Milano, Stephane, et al.
Publicado: (2019)

FRI078 Real-World Weight Loss Outcomes And Safety Of Tirzepatide, A Novel Dual GIP And GLP-1 Receptor Agonist
por: Fansa, Sima, et al.
Publicado: (2023)

SAT675 GLP-1RA Therapy And Intussusception: A Case Report Of Bowel Telescoping In Anobese Patient After Successful Weight Loss On Therapy
por: Alqaisi, Sura, et al.
Publicado: (2023)

Weight Loss, Improved Body Composition and Fat Distribution by Tesomet in Acquired Hypothalamic Obesity
por: Huynh, Kim D, et al.
Publicado: (2021)

SAT-100 Trial-in-Progress: ZEPHYR, a Pivotal Phase 2b/3 Randomized, Placebo-Controlled Study of Livoletide, a Novel Unacylated Ghrelin Analog, for the Treatment of Hyperphagia and Food-Related Behaviors in Patients with Prader-Willi Syndrome
por: Allas, Soraya, et al.
Publicado: (2019)

Timing of Onset of Adverse Events With Setmelanotide, an MC4R Agonist, in Patients With Severe Obesity Due to LEPR or POMC Deficiency
por: Clément, Karine, et al.
Publicado: (2021)

FRI059 Long-term Follow-up On Partial Lipodystrophy Treated With Leptin Receptor Agonist Mibavademab(REGN4461)
por: Foss de Freitas, Maria Cristina, et al.
Publicado: (2023)

FRI063 Effectiveness Of Liraglutide In Treating Obesity And Improving Hepatic Steatosis
por: Alfadda, Assim Abdulaziz, et al.
Publicado: (2023)

A Phase 3 Trial in Participants With Obesity Due to Bardet-Biedl Syndrome or Alström Syndrome: Efficacy and Safety of the Melanocortin 4 Receptor Agonist Setmelanotide
por: Haws, Robert, et al.
Publicado: (2021)

SAT-LB101 Loss of GLP-2R Signaling Activates Hepatic Stellate Cells and Exacerbates Diet-Induced Steatohepatitis in Mice
por: Fuchs, Shai Z, et al.
Publicado: (2020)

OR10-03 Murine Bimagrumab Co-administration With Incretin Agonists Results In Additive Efficacy And Superior Quality Weight Loss In The Mouse Diet-induced Obesity Model
por: Nguyen, Kevin, et al.
Publicado: (2023)

OR01-1 Leveraging Immunometabolic Control to Prevent and Treat Obesity Related Asthma
por: Burak, M. Furkan, et al.
Publicado: (2019)

Untangling the Heterogeneity of Acquired Generalized Lipodystrophy
por: Cavdar, Umit, et al.
Publicado: (2021)

PSUN124 Weight Loss from Combination Anti-Obesity Medications Including Glucagon-Like Peptide-1 Receptors Agonists can Approach that Achieved from Bariatric Surgery
por: Bomberg, Eric M, et al.
Publicado: (2022)

SUN-602 Weight Loss After Glucagon-Like Peptide-1 Receptor Agonist Treatment in Childhood Obesity with Diabetes and Cirrhosis Associated with a Homozygous MC4R Mutation
por: Klee, Philippe, et al.
Publicado: (2020)

SAT668 Can We Treat Osteoporosis, Obesity And Neurodegeneration With A Single FSH-blocking Drug?
por: Rani Pallapati, Anusha Rani, et al.
Publicado: (2023)

FRI075 Single Center Retrospective Matched Cohort Study Of glp1ra-induced Weight Loss In Patients With Post-bariatric Weight Regain Vs Non-surgical Controls
por: Carmen Rivadeneira, Ana Del, et al.
Publicado: (2023)

FRI066 Treatment History And Comorbidities Reported By Patients With Hypothalamic Obesity Treated With Setmelanotide In A Phase 2 Trial
por: Roth, Christian L, et al.
Publicado: (2023)

MON-LB100 Novel Paradoxical Markers of Weight Loss: Is the Worse Actually the Better? a Retrospectiveanalysisof 1,567 Patientswith Obesity With Successful Clinical Weight-Loss Approaches
por: Cadegiani, Flavio, et al.
Publicado: (2020)

FRI038 Differences In Bone Accrual Over One Year In Young Girls With Obesity Compared To Normal Weight Controls
por: Kaur, Snimarjot, et al.
Publicado: (2023)

OR10-05 Improved Mental And Psychosocial Patient-Reported Outcomes Among People With Obesity Treated With Tirzepatide: Results From SURMOUNT-1 Study
por: Poon, Jiat Ling, et al.
Publicado: (2023)

FRI072 Biomechanical CT To Assess Bone After Sleeve Gastrectomy In Adolescents With Obesity- Prospective Longitudinal Study
por: Singhal, Vibha, et al.
Publicado: (2023)

OR33-02 The Treatment of Partial Lipodystrophy in the Setting of Neutralizing Antibody Against Metreleptin with Leptin Receptor Agonist REGN4461
por: Akinci, Baris, et al.
Publicado: (2020)

FRI057 Drug Concentrations And Dosing Considerations For Mibavademab, A Novel Leptin Receptor Agonist, In Individuals With Generalized Lipodystrophy
por: Mendell, Jeanne, et al.
Publicado: (2023)

FRI071 Changes In Branched-chain Amino Acids One-year After Sleeve Gastrectomy In Youth With Obesity And Its Association With Changes In Insulin Resistance
por: Becetti, Imen, et al.
Publicado: (2023)

SUN-610 Acquired Generalized Lipodystrophy: A Rare Side Effect of PD1-Inhibitor Therapy
por: Shah, Amy, et al.
Publicado: (2020)

FRI058 Treatment With Mibavademab, A Novel Leptin Receptor Agonist, Is Associated With Improvement In Metabolic Parameters In Individuals With Generalized Lipodystrophy
por: Olenchock, Ben, et al.
Publicado: (2023)

FRI069 Treatment With Mibavademab, A Novel Leptin Receptor Agonist, Is Associated With Improvement In Weight And Associated Comorbidities In Congenital Leptin Deficiency
por: Ozsu, Elif, et al.
Publicado: (2023)

SAT649 Org43553, The First Low-molecular-weight Agonist Of The Human Luteinizing Hormone Receptor Induces Leanness And Energy Expenditure In Mice
por: Lizneva, Daria, et al.
Publicado: (2023)

ODP009 Obesity-related Conditions in Adults with Overweight and Obesity in the United States: A Cluster Analysis
por: Chiu, Kevin, et al.
Publicado: (2022)

SAT664 Obesity And Overweight Diagnosis, Physician Prescription And Patient Filling Of Anti-Obesity Medications In US
por: Ezendu, Kyrian, et al.
Publicado: (2023)

Dextroamphetamine Treatment for Children With Hypothalamic Obesity
por: van Schaik, Jiska, et al.
Publicado: (2021)

FRI083 Identifying Determinants Of Change In Physical Activity In Women With Obesity And Infertility Following The Obesity-Fertility Program
por: Gélinas, Myriam, et al.
Publicado: (2023)

Effects of Colchicine on Measures of Lipolysis in Adults With Obesity
por: Sarrafan-Chaharsoughi, Zahra, et al.
Publicado: (2021)

OR20-4 NMRI-metabolomics Variables Associated With The Metabolically-healthy Obese Phenotype And The Transitions Between Metabolically-healthy And Unhealthy Obesity Phenotypes.
por: Vargas-Vazquez, Arsenio, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_rhb9njliqhr0vrh29kkfvssto5